YF-VAX 1 dose vials
Ended Awarded Last action
- Contract number
- SPE2DR26FQHU9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $2,518
Award facts
- Contract value 100% obligated
- $2,518.16 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $2,518.16 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of YF-VAX (yellow fever vaccine) in one-dose vials. The contract, issued on January 23, 2026, with an ultimate completion date of February 13, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating that DMS Pharmaceutical Group competed against other vendors in an unrestricted procurement process. This delivery order is issued under DMS Pharmaceutical Group's broader Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a ceiling value of $499,999,999 through December 31, 2036.
DMS Pharmaceutical Group's role as a prime vendor under the PPV-G GEN V program positions it as a critical supplier within the Department of Defense's global pharmaceutical supply chain, authorized to furnish a comprehensive range of prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. The company's established performance across numerous delivery orders spanning multiple therapeutic categories and product lines demonstrates its capability to meet the specialized pharmaceutical requirements of federal military medical operations. The PPV-G GEN V initiative is part of the Defense Logistics Agency's broader $30.3 billion acquisition strategy to ensure reliable pharmaceutical supply to Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FQHU9?
SPE2DR26FQHU9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FQHU9 worth?
The government has obligated $2,518 on SPE2DR26FQHU9.
Is contract SPE2DR26FQHU9 an order under another contract?
Yes. SPE2DR26FQHU9 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHU9 competed?
The extent of competition for SPE2DR26FQHU9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award